Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Up 225.0% in January

Cocrystal Pharma, Inc. (NASDAQ:COCPGet Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 2,600 shares, an increase of 225.0% from the January 15th total of 800 shares. Based on an average daily trading volume, of 18,400 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the stock are sold short.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently raised its stake in Cocrystal Pharma stock. Renaissance Technologies LLC grew its position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCPFree Report) by 5.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 119,828 shares of the company’s stock after buying an additional 5,800 shares during the quarter. Renaissance Technologies LLC owned approximately 1.18% of Cocrystal Pharma worth $238,000 as of its most recent filing with the Securities and Exchange Commission. 13.43% of the stock is currently owned by hedge funds and other institutional investors.

Cocrystal Pharma Trading Up 0.7 %

Shares of COCP opened at $1.54 on Tuesday. The stock has a market cap of $15.66 million, a PE ratio of -0.73 and a beta of 1.38. Cocrystal Pharma has a 1 year low of $1.38 and a 1 year high of $3.29. The stock has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.98.

Cocrystal Pharma (NASDAQ:COCPGet Free Report) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.06. On average, sell-side analysts forecast that Cocrystal Pharma will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright decreased their target price on shares of Cocrystal Pharma from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, January 3rd.

Check Out Our Latest Stock Analysis on COCP

Cocrystal Pharma Company Profile

(Get Free Report)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

Read More

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with's FREE daily email newsletter.